Department of Biomedical Engineering, Vanderbilt University, Nashville, United States
Katherine M Young
Department of Biomedical Engineering, Vanderbilt University, Nashville, United States
Lauren A Hapach
Department of Biomedical Engineering, Vanderbilt University, Nashville, United States; Department of Biomedical Engineering, Cornell University, Ithaca, United States
Caroline M Carlson
Department of Biomedical Engineering, Vanderbilt University, Nashville, United States
Jenna A Mosier
Department of Biomedical Engineering, Vanderbilt University, Nashville, United States
Tanner J McArdle
Vanderbilt University Medical Center, Nashville, United States
CHU de Québec-Université Laval Research Center (Oncology division), UniversitéLaval Cancer Research Center and Faculty of Medicine, Université Laval, Québecc, Canada
Marc A Antonyak
Department of Biomedical Science, Cornell University, Ithaca, United States
Richard A Cerione
Department of Biomedical Science, Cornell University, Ithaca, United States
Cancer cell migration is highly heterogeneous, and the migratory capability of cancer cells is thought to be an indicator of metastatic potential. It is becoming clear that a cancer cell does not have to be inherently migratory to metastasize, with weakly migratory cancer cells often found to be highly metastatic. However, the mechanism through which weakly migratory cells escape from the primary tumor remains unclear. Here, utilizing phenotypically sorted highly and weakly migratory human breast cancer cells, we demonstrate that weakly migratory metastatic cells disseminate from the primary tumor via communication with stromal cells. While highly migratory cells are capable of single cell migration, weakly migratory cells rely on cell-cell signaling with fibroblasts to escape the primary tumor. Weakly migratory cells release microvesicles rich in tissue transglutaminase 2 (Tg2) which activate murine fibroblasts and lead weakly migratory cancer cell migration in vitro. These microvesicles also induce tumor stiffening and fibroblast activation in vivo and enhance the metastasis of weakly migratory cells. Our results identify microvesicles and Tg2 as potential therapeutic targets for metastasis and reveal a novel aspect of the metastatic cascade in which weakly migratory cells release microvesicles which activate fibroblasts to enhance cancer cell dissemination.